AERAMI THERAPEUTICS LOGO-VERTICAL- COLOR.png
Aerami Therapeutics Announces Orphan Drug Designation for Imatinib for the Treatment of Pulmonary Arterial Hypertension
August 25, 2021 09:00 ET | Aerami Therapeutics Inc
Pulmonary arterial hypertension (PAH) affects almost 68,000 patients worldwide, with treatment limited to vasodilators, none of which are disease-modifyingDosing of patients in Phase 1 trial is...
AERAMI THERAPEUTICS LOGO-VERTICAL- COLOR.png
Aerami Therapeutics Signs License Agreement with Hangzhou Chance Pharmaceuticals Co. Ltd. for Aerami’s PAH (pulmonary arterial hypertension) Drug Device Combination in China
February 09, 2021 09:00 ET | Aerami Therapeutics Inc
DURHAM, N.C., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. (“Aerami” or the “Company”) a clinical stage biopharmaceutical company developing inhaled therapies to treat severe...